Drug Profile
Research programme: protein therapeutics - Arecor/Eli lilly and Company
Latest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Arecor; Eli Lilly and Company
- Class Peptides; Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 22 Sep 2022 Early research development is ongoing in United kingdom (Arecor pipeline, September 2022)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom
- 23 Dec 2011 Early research in Undefined indication in United Kingdom (unspecified route)